GLP-1 Drugs Show Promise in Reducing Cancer Risk in Patients with Obesity

A new study published in JAMA Oncology suggests that GLP-1 receptor agonists (GLP-1 RAs), a popular class of drugs used for weight loss and diabetes, may also significantly reduce the risk of many obesity-related cancers. The findings from this large-scale retrospective study provide crucial insights into the long-term benefits of these medications as their use continues to expand globally.

The Study: A Deeper Look into GLP-1s and Cancer

Researchers used real-world data from the OneFlorida+ health research network to analyze the health records of 86,632 adults with obesity or overweight. The study compared the incidence of 14 cancer types in patients who were prescribed a GLP-1 RA versus a control group of non-users.

The results showed that overall, GLP-1 RA use was associated with a 17% lower risk of cancer. This protective effect was observed across a majority of the cancer types studied, with some showing a particularly significant risk reduction:

Ovarian cancer: 47% lower risk
Endometrial cancer: 25% lower risk
Meningioma: 31% lower risk
Lung cancer: 24% lower risk
Breast cancer: 14% lower risk

The consistent trend toward lower cancer incidence across different types suggests that GLP-1s may have a broad, protective effect against cancer. The study’s authors hypothesize that these drugs may be particularly effective in reducing the risk of hormone-sensitive cancers.

An Exception and a Call for Continued Research

While the study’s findings are overwhelmingly positive, there was one notable exception. The data suggested a potential 38% higher risk of kidney cancer in GLP-1 users. However, this finding was considered marginal, and the researchers noted that more long-term data is needed to fully understand this potential risk.

As GLP-1 RAs are increasingly prescribed for a variety of conditions, from heart disease to liver fibrosis, understanding their full range of long-term effects is critical for patient safety. This study is an important step in that direction, highlighting the potential of these drugs to be a powerful public health tool that goes beyond weight management. The findings call for ongoing surveillance and research to clarify the mechanisms behind both the protective effects and the potential risks.